7989948

Source:http://linkedlifedata.com/resource/pubmed/id/7989948

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0026764, umls-concept:C0040808, umls-concept:C0087111
pubmed:issue	12
pubmed:dateCreated	1995-1-12
pubmed:abstractText	This prospective study was undertaken to evaluate the efficacy of combination chemotherapy with alternating cycles of vincristine, doxorubicin, and dexamethasone (VAD) and prednisone, vindesine, carmustine, and cyclophosphamide (PECC) in poor-risk multiple myeloma (MM).
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309333
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Carmustine, http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide, http://linkedlifedata.com/resource/pubmed/chemical/Dexamethasone, http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/Prednisone, http://linkedlifedata.com/resource/pubmed/chemical/Vincristine, http://linkedlifedata.com/resource/pubmed/chemical/Vindesine
pubmed:status	MEDLINE
pubmed:month	Dec
pubmed:issn	0732-183X
pubmed:author	pubmed-author:BenboubkerLL, pubmed-author:ColombatPP, pubmed-author:CombeMM, pubmed-author:DelainMM, pubmed-author:GoupillePP, pubmed-author:LamagnèreJ PJP, pubmed-author:LinassierCC, pubmed-author:LuthierFF, pubmed-author:PetitdidierCC, pubmed-author:ReisenleiterMM
pubmed:issnType	Print
pubmed:volume	12
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	2706-13
pubmed:dateRevised	2006-4-24
pubmed:meshHeading	pubmed-meshheading:7989948-Adult, pubmed-meshheading:7989948-Aged, pubmed-meshheading:7989948-Aged, 80 and over, pubmed-meshheading:7989948-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:7989948-Carmustine, pubmed-meshheading:7989948-Cyclophosphamide, pubmed-meshheading:7989948-Dexamethasone, pubmed-meshheading:7989948-Doxorubicin, pubmed-meshheading:7989948-Female, pubmed-meshheading:7989948-Follow-Up Studies, pubmed-meshheading:7989948-Humans, pubmed-meshheading:7989948-Male, pubmed-meshheading:7989948-Middle Aged, pubmed-meshheading:7989948-Multiple Myeloma, pubmed-meshheading:7989948-Neoplasm Staging, pubmed-meshheading:7989948-Prednisone, pubmed-meshheading:7989948-Prognosis, pubmed-meshheading:7989948-Prospective Studies, pubmed-meshheading:7989948-Regression Analysis, pubmed-meshheading:7989948-Survival Analysis, pubmed-meshheading:7989948-Treatment Outcome, pubmed-meshheading:7989948-Vincristine, pubmed-meshheading:7989948-Vindesine
pubmed:year	1994
pubmed:articleTitle	VAD-PECC regimen in the treatment of advanced-stage multiple myeloma.
pubmed:affiliation	Department of Hematology/Oncology, Hôpital Bretonneau, Tours, France.
pubmed:publicationType	Journal Article, Clinical Trial, Multicenter Study